I look at it long-term. I've figured that we'll eventually get to 30 million shares fully diluted, which would add another 8 million in dilution. At an average issuance price of $30, that would be $240 million with another $40 million plus in options that could be exercised and the pivotal trial reimbursement should bring in around $25 million. So that $300 million potentially raised over the next few years at the current cash burn would provide 6 years of capital.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-10
Add to My Watchlist
What is My Watchlist?
